A study of the immune response to vaccination in MS patients treated with alemtuzumab.

Trial Profile

A study of the immune response to vaccination in MS patients treated with alemtuzumab.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2011

At a glance

  • Drugs DT-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Pneumococcal vaccine
  • Indications Diphtheria; Haemophilus infections; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Acronyms CAM-VAC
  • Most Recent Events

    • 16 Nov 2011 Planned end date changed from 23 Jun 2013 to 28 Jul 2011 as reported by European Clinical Trials Database.
    • 16 Nov 2011 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 15 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top